Prevention of viral hepatitis in the Nordic countries and Germany

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 8, 2005, Pages 549-560

  Fitzsimons, David ^a   François, Guido ^b   Alpers, Katharina ^c   Radun, Doris ^c   Hallauer, Johannes ^d   Jilg, Wolfgang ^e   Gerlich, Wolfram ^f   Rombo, Lars ^g   Blystad, Hans ^h   Nøkleby, Hanne ^h   van Damme, Pierre ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ROBERT KOCH INSTITUTE   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS VACCINE; METHADONE;

ARTICLE; AWARENESS; DENMARK; DIAGNOSTIC TEST; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; FINLAND; GERMANY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; ICELAND; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; MEDICAL EXPERT; NONHUMAN; NORWAY; POLITICS; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SIDE EFFECT; SWEDEN; VACCINATION; VIRUS HEPATITIS; VIRUS VIRULENCE;

ADOLESCENT; ADULT; CHILD; DISEASE OUTBREAKS; FEMALE; GERMANY; HEPATITIS, VIRAL, HUMAN; HOMOSEXUALITY, MALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; POPULATION SURVEILLANCE; SCANDINAVIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 24644481936     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540510043284     Document Type: Article

References (46)

1. Iwarson S. Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK). Vaccine 1998;16 (Spppl): S63-4.
2. Jensen L, Heilmann C, Smith E, Wantzin P, Peitersen B, Weber T, Krogsgaard K. Efficacy of selective antenatal screening for hepatitis B among pregnant women in Denmark: is selective screening still an acceptable strategy in a low-endemicity country? Scand J Infect Dis 2003;35:378-82.
3. Böttiger M, Christenson B, Grillner L. Hepatitis A immunity in the Swedish population. A study of the prevalence of markers in the Swedish population. Scand J Infect Dis 1997; 29:99-102.
4. Pebody RG, Ruutu P, Nohynek H, Leinikki P. Changing epidemiology of hepatitis B infection in Finland. Scand J Infect Dis 1999;31:251-4.
5. Christensen PB, Krarup HB, Niesters HG, Norder H, Schaffalitzky de Muckadell OB, Jeune B, Georgsen J. Outbreak of hepatitis B among injecting drug users in Denmark. J Clin Virol 2001;22:133-41.
6. European Monitoring Centre for drugs and drug addiction (EMCDDA). Annual report 2003: the state of the drugs problem in the European Union and Norway. Lisbon 2003.
7. Miller M, Mella I, Moi H, Eskild A. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. J AIDS 2003;33:373-9.
8. Bundesgesetzblatt. Infection Protection Act: Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen (Infektionsschutzgesetz-IfSG). 2000; 1045.
9. Müller HE. Notification according to the law for protection against infections. Gesundheitswesen 2001;63:755-8.
10. Robert Koch-Institut. Falldefinitionen des Robert Koch-Instituts zur Übermittlung von Erkrankungs-oder Todesfällen und Nachweisen von Kranksheitserregern. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004;47:165-206. http://www.rki.de/cln_011/nn_349724/DE/Content/Infekt/ IfSG/Falldefinition/IfSG/Falldefinition,templateId=raw,property= publicationFile.pdf/Falldefinition [Accessed April 2005].
11. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001;17:429-35.
12. Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2003. Mercedes-Druck, Berlin. 2004. http://www.rki.de/cln_006/nn_226624/DE/Content/Infekt/Jahrbuch/ Jahrbuch_2003,templateId=raw,property=publicationFile.pdf/ Jahrbuch_2003. [Accessed April 2005]
13. Thefeld W. Hepatitis B Durchseuchung in der deutschen Bevölkerung. Bundesgesundhbl 1994;37:372-7.
14. Kramer A, Prufer-Kramer L. Experience with the new German hepatitis B vaccination strategy since 1995. Int J STD AIDS 2002;13(Suppl 2):35-7.
15. Robert Koch-Institut. Mitteilungen der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epi Bull 2004;30:235-50. http://www.rki.de/cln_011/nn_243990/DE/Content/Infekt/EpidBull/Archiv/ 2004/30_04,templateId=raw,property=publicationFile.pdf/30_04 [Accessed April 2005]
16. Dausch E, Jilg E. HBsAg-Screening in der Schwangerschaft - Durchführung und Effizienz. Eine Studie an 6083 Schwangeren in 11 bayerischen Kliniken. Geburtsh Frauenheilk 2001;61:676-81.
17. Mercer CH, Fenton KA, Copas AJ, Wellings K, Erens B, McManus S, et al. Increasing prevalence of male homosexual partnerships and practices in Britain 1990-2000: evidence from national probability surveys. AIDS 2004;18: 1453-8.
18. Weber B, Rabenau H, Berger A, Scheuermann EH, Staszewski S, Kreuz W, et al. Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups. Frankfurt a.M., Germany. Zbl Bakt 1995;282:102-12.
19. Kleiber D, Wilke M. 1995. AIDS, Sex und Tourismus. Ergebnisse einer Befragung deutscher Urlauber und Sextouristen. Band 33, Schriftenreihe des Bundesministeriums für Gesundheit. Baden-Baden: Nomos Verlagsgesellschaft. ISBN: 3-7890-3707-9.
20. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997;26:1359-66.
21. Chamot E, de Saussure P, Hirschel B, Deglon JJ, Perrin LH. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 1992;6:430-1.
22. Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000;32:253-8.
23. Dolan K, Rutter S, Wodak AD. Prison-based syringe exchange programmes: a review of international research and development. Addiction 2003;98:153-8.
24. Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000;18: 2095-101.
25. Bienzle U, Günther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38:811-9.
26. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C, hepatitis B infections among blood donors in Germany 2000-2002, risk of virus transmission and the impact of nucleic acid amplification testing. Eurosurveillance 2005;10:2.
27. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2: 1104-8.
28. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich WH, Günther S, et al. The serological pattern 'anti HBc alone'. Report on a workshop. J Med Virol 2000;62:450-5.
29. Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meilicke M, Schäfer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
30. Polywka S, Feucht H, Zöllner B, Laufs R. Hepatitis C virus infection in pregnancy and the risk of mother-to-child transmission. Eur J Clin Microbiol Inf Dis 1997;16: 121-4.
31. Backmund M, Meyer K, Wächtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003;18:563-8.
32. Offergeld R, Stark K, Hamouda O. Infektionen bei Blutspendern. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2003;46:775-9.
33. Ross RS, Viazov S, Renzing-Kohler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000;60:122-5.
34. Robotin MC, Copland J, Tallis G, Coleman D, Giele C, Carter L, et al. Surveillance for newly acquired hepatitis C in Australia. J Gastroent Hepatol 2004;19:283-8.
35. Wiese M, Berr F, Lafrenz M, Porst H, Ösen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicentre study. Hepatology 2000;32:91-6.
36. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
37. Ross S, Roggendorf M. 2002. Epidemiologie der hepatitis C-Infektion und das Problem nosokomialer Übertragungen durch infiziertes medizinisches Personal. In: Mauss S, Rockstroh JK, Jager H, editors. Koinfektion Hepatitis und HIV. Stuttgart: Thieme; p. 1-8.
38. Cockcroft A. Surgeons who test positive for hepatitis C should not be transferred to low risk duties. Rev Med Virol 2000;10:79-82.
39. Heptonstall J. Surgeons who test positive for hepatitis C should be transferred to low risk duties. Rev Med Virol 2000;10:75-8.
40. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch Intern Med 2000;160:2313-6.
41. Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, et al. on behalf of the European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003;27:213-30.
42. Gerlich W. Hepatitis B und C: Übertragungsgefahr auf Patienten durch infiziertes medizinisches Personal. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47:369-78.
43. DVV (Deutsche Vereinigung zur Bekämpfung von Viruskrankheiten). Empfehlungen zur Verhütung der Übertragung von hepatitis-C-Virus durch infiziertes Personal im Gesundheitsdienst. Epidemiologisches Bulletin 2001;3:15-6. http://www.rki.de/cln_011/nn_244010/DE/Content/Infekt/EpidBull/Archiv/ 2001/03_01,templateId=raw,property=publicationFile.pdf/03_01 [Accessed April 2005]
44. DVV (Deutsche Vereinigung zur Bekämpfung von Viruskrankheiten). 2004. Empfehlungen zur Prävention der nosokomialen Übertragung von hepatitis B Virus (HBV) und hepatitis C Virus (HCV) durch im Gesundheitswesen Tätige (as of January 2004) In: Ross RS, Roggendorf M, editors. Übertragungsrisiko von HBV, HCV und HIV durch infiziertes medizinisches Personal. Lengerich, Berlin, Riga, Rom, Wien, Zagreb: Pabst Science Publishers.
45. Ross SR, Roggendorf M (editors). 2004. Übertragungsrisiko von HBV, HCV und HIV durch infiziertes medizinisches Personal. Lengerich, Berlin, Riga, Rom, Wien, Zagreb: Pabst Science Publishers.
46. Bricout F, Moraillon A, Sonntag P, Hörner P, Blackwelder W, Plotkin S. Virus-inhibiting surgical glove to reduce the risk of infection by enveloped viruses. J Med Virol 2003;69: 538-45.